Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2024.04.29.591613

Oligomerization and cellular localization of SLC26A11

Bungert-Pluemke, S.·Guzman, R. E.·Fahlke, C.
View original source ↗Export metadata ↓

Abstract

The solute carrier family 26 (SLC26) encompasses multifunctional anion exchangers in all kingdoms of life. SLC26 proteins are known to assemble as dimers, and co-expression of multiple isoforms in certain cells raises the question whether different SLC26s can assemble into hetero-dimers. We focused on SLC26A11, a broadly expressed isoform that differs from other isoforms in its subcellular localization. Whereas the vast majority of SLC26-FP fusion proteins, i.e. SLC26A1, SLC26A2, SlC26A3, SLC26A4/pendrin, SLC26A5/prestin, SLC26A6, SlC26A7, and SLC26A9, localize to the surface membrane of transfected mammalian cells, we found exclusive lysosomal localization of SLC26A11. Renal collecting duct intercalated cells express SLC26A11 together with SLC26A4/pendrin and SLC26A7, and we therefore tested whether heterodimerization between these transporters might result in SLC26 transporter re-localization. Neither in HEK293T nor in immortalized intercalated cells co-expressing SLC26A11 with SLC26A4/pendrin or with SLC26A7, changes of SLC26A11 localization were observed. Moreover, native gel electrophoresis did not provide any evidence for heterodimerization of these isoforms. We next tested heterodimerization of SLC26A11 with SLC26A1, SLC26A2, SLC26A6 or SLC26A9 via co-expression in HEK293T cells and confocal imaging. For all combinations, no changes in subcellular distribution were observed. We conclude that SLC26A11 does not heterodimerize with other SLC26 proteins, and that heterodimerization does not target SLC26A11 to cellular surface membranes.

Explore related subjects

cell biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bungert-Pluemke, S., Guzman, R. E., Fahlke, C.. 2024-05-01. Oligomerization and cellular localization of SLC26A11. https://doi.org/10.1101/2024.04.29.591613

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗
bioRxiv2026

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗
bioRxiv2026

Matrix Gla Protein deficiency reveals a previously unrecognized mucosal calcification in the mouse airways

Tracheal calcification is a common finding that is considered to have limited clinical significance when detected most often in elderly individuals. Despite its frequent occurrence, the cellular and molecular mechanisms at the origin of tracheal calcification remain largely unexplored. In this context, we aimed to characterize the development of tracheal calcification, and to determine the role of matrix Gla protein (MGP), a major inhibitor of ectopic calcification whose genetic or pharmacologic deficiency is associated with premature tracheal calcification in humans. We found that wild-type mice undergo an unexpected early physiologic calcification of the tracheal cartilage rings beginning around one month after birth. This calcification progresses in a dynamic rostro-caudal sequence through a process involving terminal differentiation of tracheal chondrocytes. These findings challenge the prevailing view that tracheal cartilage is a permanent hyaline cartilage and instead reveals an early and highly organized physiologic calcification process. Furthermore, our findings further identify MGP as a key regulator of calcification within the respiratory tract. Indeed, MGP deficiency not only markedly accelerates tracheal cartilage calcification through a similar pattern and mechanism but also induces a previously unrecognized calcification of the tracheal mucosa, a lesion absent in wild-type mice. These alterations could partly explain the respiratory manifestations observed in MGP-deficient patients having Keutel syndrome, which include dyspnea, cough, stridor, and recurrent infections, symptoms previously being mainly attributed to calcification of the tracheal cartilage rings.

cell biology↗